MSCI Biotech Advance Indexes
Research Paper
August 7, 2024
Preview
The health-care sector, particularly the biotech space, is encountering both opportunities and challenges in the post-pandemic world. Primary among these challenges is a looming patent cliff, created by many leading drugs losing their patent protection between 2025 and 2035. This loss is anticipated to cause a substantial decline in the worldwide sales of major drugs, paving the way for generics and biosimilars, a nearly identical copy of the original product manufactured by a different company. It also presents opportunities for companies to fuel research, accelerate drug development pipelines and bring innovative treatments to market faster.
The MSCI Biotech Advance Indexes, composed of companies at the forefront of innovation in drug development and therapeutics, are designed to reflect the changing biotech space over the coming years.
Historical sales impact of major drugs going off patent
We show the annual reported worldwide sales of major products expiring in each year from 1986 through 2023 and forecasted worldwide sales through 2030. Eligible products are based on new chemical or biological entities with over USD 10 billion in 2023 worldwide sales. Source: Evaluate Pharma
Read the full paper
Read the full paper
Provide your information for instant access to our research papers.
Thematic Investing
Thematic investing is a future-focused approach that relies on deep research to capitalize on macroeconomic, geopolitical and technological trends expected to evolve over time.
MSCI Life Sciences Indexes
Our suite of MSCI Life Sciences Indexes aims to represent long-term, future-focused themes that are expected to disrupt the life sciences, biotechnology and pharmaceutical industries.
Innovation Creates Opportunity within Life Sciences
The pharmaceutical industry is experiencing a faster pace of disruption thanks to frequent technological breakthroughs.
The content of this page is for informational purposes only and is intended for institutional professionals with the analytical resources and tools necessary to interpret any performance information. Nothing herein is intended to recommend any product, tool or service. For all references to laws, rules or regulations, please note that the information is provided “as is” and does not constitute legal advice or any binding interpretation. Any approach to comply with regulatory or policy initiatives should be discussed with your own legal counsel and/or the relevant competent authority, as needed.